There are a couple of things that i noticed.
"Late in 2015, following the completion of their public comment period for 2016 reimbursement guidance, we met with CMS to evaluate the pathway for separate transitional add-on reimbursement for Triferic�. Since then, we have been actively working to obtain transitional add-on reimbursement for Triferic�, which would allow customers to receive a separate, higher reimbursement for Triferic"
So it appears that they applied for transitional add-on reimbursement after they met with CMS. Maybe it was suggested to them or they were told to go for this?! Maybe there is a greater chance to get approval than we thought!
We continued our sales and market development work with Triferic� while we work to obtain transitional add on reimbursement for the drug. Until we obtain transitional add-on reimbursement, or until we cease trying to obtain it, we expect Triferic� sales activity to not be significant."
As it has being said here by others before. Maybe, clients are waiting to sign contracts because they are waiting for this to be resolved. Once it is, one way or another, we may see a couple of clients come on board. At least that is what i think. I am long RMTI. What do you guys think?